Figure 2

Subgroup analyses of SVR12 (per-protocol set). FIB-4 fibrosis index based on four factors; GLE/PIB glecaprevir/pibrentasvir; SOF/VEL sofosbuvir/velpatasvir; HBV hepatitis B virus; HCC hepatocellular carcinoma; RNA ribonucleic acid; SVR12 sustained virological response 12 weeks after treatment cessation.